A randomized phase II study of gemcitabine plus S-1 versus gemcitabine alone in patients with unresectable pancreatic cancer.

被引：0
|
作者：
Omuro, Y.
Ikari, T.
Ishii, H.
Ozaka, M.
Suyama, M.
Matsumura, Y.
Itoi, T.
Egawa, N.
Yano, S.
Hanada, K.
Kimura, Y.
Ukita, T.
Ishida, Y.
Tani, M.
Ohoka, S.
Hirose, Y.
Hijioka, S.
Watanabe, R.
Ikeda, T.
Nakajima, T.
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[2] Tobu Chiiki Hosp, Tokyo, Japan
[3] Canc Inst Hosp, Tokyo, Japan
[4] Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan
[5] Juntendo Univ Hosp, Tokyo, Japan
[6] Tokyo Med Univ, Tokyo 1608402, Japan
[7] Kanazawa Univ, Kanazawa, Ishikawa, Japan
[8] JA Onomichi Gen Hosp, Hiroshima, Japan
[9] Sapporo Med Univ Hosp, Sapporo, Hokkaido, Japan
[10] Toho Univ, Ohashi Med Ctr, Tokyo, Japan
[11] Kurume Univ Hosp, Kurume, Fukuoka, Japan
[12] Wakayama Med Univ Hosp, Wakayama, Japan
[13] Tokyo Med & Dent Univ Hosp, Tokyo, Japan
[14] Fukui Red Cross Hosp, Fukui, Japan
[15] Kumamoto Red Cross Hosp, Kumamoto, Japan
[16] Matsuyama Shimin Hosp, Matsuyama, Japan
[17] Yokosuka Kyosai Hosp, Yokosuka, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4029
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer.
    Ohkawa, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 346S - 346S
  • [32] Efficacy and safety of S-1 and gemcitabine in an unselected Western cohort of patients with unresectable pancreatic cancer.
    Pfeiffer, Per
    Bjerregaard, Jon Kroll
    Schoennemann, Katrine R.
    Weisz, Mathilde Korsgaard
    Winther, Stine Braendegaard
    Jensen, Helle Anita
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
    Scott, Aaron James
    O'Neil, Bert H.
    Ma, Wen Wee
    Cohen, Steven J.
    Aisner, Dara
    Menter, Alex R.
    Tejani, Mohamedtaki Abdulaziz
    Cho, Jonathan K.
    Rubin, Peter
    Coveler, Andrew L.
    Olowokure, Olugbenga Olanrele
    Baranda, Joaquina Celebre
    Cusnir, Mike
    Philip, Philip Agop
    Boles, Jeremiah
    Maguire, Robert T.
    Wilhelm, Francois
    Maniar, Manoj
    Gomes, Christina
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
    Jin, Min
    Liu, Hong-Li
    Xue, Jun
    Ma, Hong
    Liu, Jun-Li
    Lin, Zhen-Yu
    Wang, Jing
    Bao, Le-Qun
    Luo, Zhi-Guo
    Yu, Xiong-Jie
    Li, Shuang
    Hu, Jian-Li
    Zhang, Tao
    ONCOLOGIST, 2024, 29 (10): : e1406 - e1418
  • [35] Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer
    Hunho Song
    Boram Han
    Choong Kee Park
    Jong Hyeok Kim
    Jang Yong Jeon
    In-Gyu Kim
    Hyo Jung Kim
    Joo Young Jung
    Jung Han Kim
    Jung Hye Kwon
    Geundoo Jang
    Ho Young Kim
    Hyeong Su Kim
    Dae Ro Choi
    Dae Young Zang
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 845 - 852
  • [36] Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer
    Song, Hunho
    Han, Boram
    Park, Choong Kee
    Kim, Jong Hyeok
    Jeon, Jang Yong
    Kim, In-Gyu
    Kim, Hyo Jung
    Jung, Joo Young
    Kim, Jung Han
    Kwon, Jung Hye
    Jang, Geundoo
    Kim, Ho Young
    Kim, Hyeong Su
    Choi, Dae Ro
    Zang, Dae Young
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (04) : 845 - 852
  • [37] The final analysis of a multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and S-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study
    Isayama, H.
    Nakai, Y.
    Sasaki, T.
    Sasahira, N.
    Hirano, K.
    Tsujino, T.
    Tada, M.
    Omata, M.
    Koike, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201
    Loehrer, P. J., Sr.
    Powell, M. E.
    Cardenes, H. R.
    Wagner, L.
    Brell, J. M.
    Ramanathan, R. K.
    Crane, C. H.
    Alberts, S. R.
    Benson, A. B., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial
    Loehr, J. M.
    Haas, S. L.
    Bechstein, W. -O.
    Bodoky, G.
    Cwiertka, K.
    Fischbach, W.
    Foelsch, U. R.
    Jaeger, D.
    Osinsky, D.
    Prausova, J.
    Schmidt, W. E.
    Lutz, M. P.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1214 - 1222
  • [40] Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
    Borad, Mitesh J.
    Reddy, Shantan G.
    Bahary, Nathan
    Uronis, Hope E.
    Sigal, Darren
    Cohn, Allen L.
    Schelman, William R.
    Stephenson, Joe, Jr.
    Chiorean, E. Gabriela
    Rosen, Peter J.
    Ulrich, Brian
    Dragovich, Tomislav
    Del Prete, Salvatore A.
    Rarick, Mark
    Eng, Clarence
    Kroll, Stew
    Ryan, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1475 - 1481
12345